Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPALAN vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
100 mg orally twice daily
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life is 12-14 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 60 hours in severe renal impairment (Cr Cl <30 m L/min).
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Hepatic via CYP2D6 and CYP3A4; active metabolite N-desmethylserpalan.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal elimination (60-70% unchanged drug), with 20-30% biliary/fecal excretion as metabolites; less than 10% excreted unchanged in feces.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Approximately 85-90% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
~10-20% bound to plasma proteins (primarily albumin).
1.2-1.8 L/kg, indicating extensive tissue distribution (e.g., liver, kidneys, and lungs); higher Vd in obese patients.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 75-85% due to first-pass metabolism; IM: 90-98%; rectal: 50-70%.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
GFR ≥ 60 m L/min: no adjustment; GFR 30-59 m L/min: 50 mg once daily; GFR < 30 m L/min: avoid use
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: contraindicated
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not established for patients < 18 years
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Maximum 50 mg once daily due to increased sensitivity and renal impairment risk
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Suicidal thoughts and behaviors: Increased risk in children, adolescents, and young adults during initial treatment.
None
Serotonin syndrome with concomitant serotonergic drugs; risk of bleeding with NSAIDs/anticoagulants; activation of mania/hypomania; bone fracture risk in elderly; hyponatremia; QT prolongation at high doses.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to serpalan; concurrent use of MAOIs or linezolid; concurrent use of pimozide; use of MAOIs within 14 days.
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid concurrent use of alcohol; may worsen central nervous system effects. No specific food restrictions; take with or without food. Grapefruit juice has no significant interaction.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Late third trimester: neonatal withdrawal syndrome and respiratory depression.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Excreted into breast milk (M/P ratio 0.9). Not recommended during breastfeeding due to potential adverse effects on infant including sedation, poor feeding, and withdrawal. Consider alternative therapy.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Due to increased plasma volume and hepatic metabolism, dose may need to be increased by 20-30% in the second and third trimesters. Monitor trough levels and adjust to maintain therapeutic range. Postpartum, decrease dose to prepregnancy levels within 48 hours.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
SERPALAN is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic drugs. Initiate at 20 mg daily; titrate to 40 mg after 4 weeks if needed. Do not abruptly discontinue; taper gradually to avoid withdrawal symptoms. Use with caution in patients with hepatic impairment (dose reduction recommended). Avoid MAOIs within 14 days.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take this medication at the same time each day, with or without food.,Do not stop taking this medication suddenly; consult your doctor for a tapering schedule.,It may take 2–4 weeks to feel the full benefit; continue taking even if you do not notice immediate improvement.,Notify your doctor if you experience new or worsening anxiety, agitation, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not take other medications, including over-the-counter drugs, without consulting your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPALAN vs ALDOMET, answered by our medical review team.
SERPALAN is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPALAN and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPALAN is: 100 mg orally twice daily. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPALAN and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPALAN is classified as Category C. First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and thir. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.